Canada Approves First Functional Cure for Hepatitis B

Imagine facing a lifelong diagnosis, only to discover a brief course of treatment could set you free for good. That hope is now a reality for hundreds of thousands of Canadians living with chronic hepatitis B.

Health Canada just granted priority review approval to Hibsago, a groundbreaking therapy developed by GSK. It marks the first treatment in the country designed to achieve a functional cure rather than requiring patients to take pills for the rest of their lives.

Until now, managing chronic hepatitis B meant an endless routine of antiviral drugs to keep the virus suppressed. Hibsago transforms that journey into a finite regimen, targeting the genetic building blocks of the virus so the body can take over.

The medication is an antisense oligonucleotide, an intelligent biological tool engineered to seek out and silence viral RNA. By dismantling the virus's instructions and lowering surface proteins, it gives the immune system the breathing room it needs to rebuild its natural defenses.

In global clinical trials across 29 countries, the therapy yielded extraordinary results. Up to 26% of patients achieved a functional cure, keeping the virus completely undetectable for at least six months after stopping all medication.

The Ripple Effect

Achieving a functional cure does far more than lift the burden of daily prescriptions. Studies show that clearing the virus's surface protein slashes liver cancer risk by up to 89% and reduces overall mortality by 62%.

Beyond the physical relief, this milestone brings profound peace of mind to an estimated 262,000 Canadians who navigate the worry and stigma of a long-term liver condition. Families can look toward the future with confidence as medical innovation turns lifelong management into lasting health.

With rollouts planned for early 2027, a healthier, virus-free tomorrow is finally within reach.